OpenEvidence Inc.

OpenEvidence Inc. is a company focused on improving healthcare by providing a platform that aggregates clinical findings and multimedia resources for healthcare professionals, enhancing their access to crucial medical insights. OpenEvidence, founded in 2021, is dedicated to providing an extensive platform for healthcare professionals to access relevant clinical findings. The company is based in Cambridge, US.

OpenEvidence primarily offers a platform designed to facilitate access to multimedia and clinical findings, specifically for healthcare professionals. The platform aggregates data from reputable sources such as The New England Journal of Medicine, providing a comprehensive repository of clinical insights and research findings. It serves a diverse customer base, including physicians, researchers, and healthcare organizations within the United States, focusing on enhancing clinical decision-making and improving patient outcomes through evidence-based data access. OpenEvidence generates revenue by offering its platform free of charge to healthcare professionals, fostering collaborations with institutions and organizations to enhance the dissemination of medical research.

The firm’s business model emphasizes engagement and retention rather than traditional transactional revenue, establishing itself as a critical tool for healthcare professionals to access essential medical insights and data. In January 2026, OpenEvidence Inc. raised USD 250 million in series D funding co-led by DST Global and Thrive Capital, with participation from Coatue Management, Conviction, Greycroft, GV, Kleiner Perkins, Sequoia Capital, Blackstone, Bond, Craft Ventures, ICONIQ Capital, Breyer Capital, Goanna Capital, Meritech Capital Partners, Alkeon Capital Management, and Mayo Clinic. The company plans to use the January 2026 funding to expand its medical superintelligence platform, accelerate product development, and scale operations to support doctors globally.